Amneal Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.
Amneal now expects an additional $50m in net revenue this year, revising its revenue expectations up to between $2.3bn and $2.4bn following a successful second quarter.
With a continuing focus on complex generics, Amneal has revealed a trio of US filings targeting ProAir, Lumigan and Diprivan.
Amneal says it will work closely with the FDA after seeing its application for the company’s IPX203 cardbidopa/levodopa extended-release turned down for approval by the agency.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.